CorMedix Inc. filed a Form 8-K on November 16, 2026, furnishing the transcript of its investor conference call held on November 12, 2026, which discussed financial results for the quarter ended September 30, 2026, and also disclosed details related to a proposed acquisition of substantially all of the assets of Heron Therapeutics, Inc.
Key Highlights
- Conference call date: CorMedix hosted its investor conference call and webcast on November 12, 2026, to discuss third-quarter financial results for the period ended September 30, 2026.
- Transcript furnished: The call transcript is attached as Exhibit 99.1 and incorporated by reference into the filing.
- Proposed acquisition disclosed: The filing references a proposed acquisition by CorMedix of substantially all of the assets of Heron Therapeutics, Inc., described in the filing as the "Proposed Acquisition."
- Proxy statement anticipated: According to the filing, Heron Therapeutics intends to file a proxy statement on Schedule 14A with the SEC in connection with the Proposed Acquisition.
- Private placement noted: The filing states that CorMedix common stock to be issued to Heron in the Proposed Acquisition "will be issued in a private placement in reliance on an exemption from the registration requirements of the Securities Act."
- Soliciting material designation: The filing is checked as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
CorMedix Q3 2026 Call Transcript and Heron Therapeutics Acquisition Disclosure
CorMedix Inc. (NASDAQ:CRMD), headquartered in Parsippany, NJ, filed a Current Report on Form 8-K dated November 12, 2026, with the filing made on November 16, 2026. The report was submitted under Item 7.01 Regulation FD Disclosure and furnishes the transcript of the company's investor conference call covering its financial results for the quarter ended September 30, 2026. According to the filing, the transcript is attached as Exhibit 99.1 and is incorporated by reference.
The filing notes that the information in Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." Beyond the earnings call transcript, the 8-K contains extensive disclosures relating to a proposed transaction in which CorMedix would acquire substantially all of the assets of Heron Therapeutics, Inc. The filing states that Heron intends to file a proxy statement on Schedule 14A with the SEC in connection with the Proposed Acquisition, and that both CorMedix and Heron "has and may file relevant documents with the SEC regarding the Proposed Acquisition." The filing urges investors and stockholders to read those documents when available.
The filing also identifies CorMedix and Heron, along with their respective directors and executive officers, as potential participants in the solicitation of proxies from Heron's stockholders. It directs readers to CorMedix's proxy statement for its 2026 annual meeting of stockholders, filed with the SEC on April 29, 2026, and Heron's proxy statement for its 2026 annual meeting of stockholders, filed with the SEC on April 30, 2026, for additional information on those participants. The filing contains forward-looking statements, which the company identifies as subject to risks and uncertainties under its cautionary language, covering topics including the anticipated benefits of the Proposed Acquisition, expected synergies, revenue diversification, and the potential for the transaction to be "accretive to earnings."
What Was Disclosed
CorMedix filed an 8-K furnishing the transcript of its November 12, 2026 earnings call for the quarter ended September 30, 2026, and including disclosures about a proposed acquisition of substantially all of Heron Therapeutics' assets, with Heron expected to file a related proxy statement with the SEC.




Please wait processing your request...